We have located links that may give you full text access.
English Abstract
Journal Article
[Correlation between the expression of vascular endothelial growth factor and prognosis of lung cancinoma].
Chinese Journal of Tuberculosis and Respiratory Diseases 1999 September
OBJECTIVE: To determine the association between the expression of vascular endothelial growth factor (VEGF) and prognosis of lung cancer.
METHODS: Apply the SP immunohistochemistry stain method to investigate the expression of VEGF in 60 specimens of patients with lung cancer, who had undergone curative resection more than 36 months before.
RESULTS: The VEGF stain positive rate is 60% in 60 cases of lung cancer specimens; The immunoreactivity of VEGF was almost exclusively restricted to the tumor cells, the positive expression of VEGF showed significantly higher in the patients with lymph node metastasis and/or relapse. The positive rates of VEGF were higher in N1, N2 groups (53%, 80%) than in No group (23%, P < 0.01), and in relapse group (80%) than in non-relapse group (53%, P < 0.05). Postoperative survival time was shorter in VEGF(+) group (31 +/- 7 months) than in VEGF(-) group (64 +/- 7 months, P < 0.05). The 3, 5 year survival rates showed significant difference between VEGF(+) (31%, 11%) and VEGF(-) (88%, 50%) groups.
CONCLUSIONS: The results suggest VEGF is a reliable prognostic parameter and antiangiogenesis therapy will be a useful strategy in treatment of the human lung cancer.
METHODS: Apply the SP immunohistochemistry stain method to investigate the expression of VEGF in 60 specimens of patients with lung cancer, who had undergone curative resection more than 36 months before.
RESULTS: The VEGF stain positive rate is 60% in 60 cases of lung cancer specimens; The immunoreactivity of VEGF was almost exclusively restricted to the tumor cells, the positive expression of VEGF showed significantly higher in the patients with lymph node metastasis and/or relapse. The positive rates of VEGF were higher in N1, N2 groups (53%, 80%) than in No group (23%, P < 0.01), and in relapse group (80%) than in non-relapse group (53%, P < 0.05). Postoperative survival time was shorter in VEGF(+) group (31 +/- 7 months) than in VEGF(-) group (64 +/- 7 months, P < 0.05). The 3, 5 year survival rates showed significant difference between VEGF(+) (31%, 11%) and VEGF(-) (88%, 50%) groups.
CONCLUSIONS: The results suggest VEGF is a reliable prognostic parameter and antiangiogenesis therapy will be a useful strategy in treatment of the human lung cancer.
Full text links
Related Resources
Trending Papers
Obesity pharmacotherapy in older adults: a narrative review of evidence.International Journal of Obesity 2024 May 7
Haemodynamic monitoring during noncardiac surgery: past, present, and future.Journal of Clinical Monitoring and Computing 2024 April 31
SGLT2 Inhibitors in Kidney Diseases-A Narrative Review.International Journal of Molecular Sciences 2024 May 2
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app